Document is current

Article History

Received: 23 February 2024

Accepted: 27 August 2024

First Online: 18 September 2024

Declarations

:

: Department of Respiratory Medicine and Neonatology of the Children’s Hospital of Chongqing Medical University had confirmed that there was ethical approval for the collection of umbilical cord tissue and human cells (Approval Number: 2022 − 347; Approval Date: October 09, 2022), and the donors’guardians had signed informed consent. All research protocols involving hUC-MSCs had been reviewed by the Institutional Ethics Committee of Chongqing Perfect Cell Biotechnology Co., Ltd. (Approval Number: KYLL-202302-04; Approval Date: February 25, 2023). All participants consented to be part of this study. This study was approved by the Institutional Ethics Committee of Chongqing Perfect Cell Biotechnology Co., Ltd. (Title: Animal experimental study on the treatment of osteoarthritis by three-dimensional hanging drop cultured umbilical cord mesenchymal stem cells; Approval Number: DWLL202303; Approval Date: September 1, 2023). All surgical procedures were performed in accordance with Guidelines for the ethical review of laboratory animal welfare People’s Republic of China National Standard GB/T 35892–2018 (Issued 6 February 2018 Effective from 1 September 2018). All experimental facilities had a national authorization to perform animal experiments (approval ID: SYXK 2020-0017). This study has been reported in line with the ARRIVE guidelines 2.0.

: Not applicable.

: The authors declare that there is no competing interests.